Clinical trial
A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function
NCT02646358 is registered in ClinicalTrials.gov with Mast Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function
- Lead sponsor
- Mast Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- Not reported
- Enrollment
- 27 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers, pharmacokinetics of vepoloxamer, renal impaired